Chongqing Lummy Pharmaceutical (300006) — Strategic Asset Allocation Index
Chongqing Lummy Pharmaceutical (300006) has a Strategic Asset Allocation Index of 14.5% as of September 2023. Strategic assets (PP&E of CN¥304.16 Million plus long-term investments of CN¥-) total CN¥304.16 Million, measured against net assets of CN¥2.10 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Chongqing Lummy Pharmaceutical liquid asset ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Chongqing Lummy Pharmaceutical Strategic Asset Allocation Index (2006–2022)
This chart shows how Chongqing Lummy Pharmaceutical's Strategic Asset Allocation Index has evolved across 17 annual periods from 2006 to 2022. As of September 2023, the index stands at 14.5%, representing strategic assets of CN¥304.16 Million against net assets of CN¥2.10 Billion CNY. See Chongqing Lummy Pharmaceutical leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Chongqing Lummy Pharmaceutical (2006–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Chongqing Lummy Pharmaceutical from 2006 to 2022, covering 17 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see how much is Chongqing Lummy Pharmaceutical worth.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 15.6% | CN¥339.92 Million | CN¥339.92 Million | CN¥- | CN¥2.18 Billion | ▼ -2.2 pp |
| 2021 | 17.7% | CN¥392.49 Million | CN¥392.49 Million | CN¥- | CN¥2.21 Billion | ▼ -19.6 pp |
| 2020 | 37.3% | CN¥459.97 Million | CN¥459.97 Million | CN¥- | CN¥1.23 Billion | ▲ +1.1 pp |
| 2019 | 36.3% | CN¥600.25 Million | CN¥600.25 Million | CN¥- | CN¥1.65 Billion | ▼ -32.6 pp |
| 2018 | 68.9% | CN¥1.19 Billion | CN¥685.83 Million | CN¥502.58 Million | CN¥1.72 Billion | ▲ +5.6 pp |
| 2017 | 63.3% | CN¥1.09 Billion | CN¥781.00 Million | CN¥309.38 Million | CN¥1.72 Billion | ▲ +4.1 pp |
| 2016 | 59.1% | CN¥990.32 Million | CN¥871.33 Million | CN¥118.99 Million | CN¥1.67 Billion | ▼ -0.1 pp |
| 2015 | 59.3% | CN¥1.00 Billion | CN¥943.09 Million | CN¥58.60 Million | CN¥1.69 Billion | ▼ -37.3 pp |
| 2014 | 96.6% | CN¥981.87 Million | CN¥981.87 Million | CN¥- | CN¥1.02 Billion | ▲ +12.1 pp |
| 2013 | 84.4% | CN¥950.29 Million | CN¥950.29 Million | CN¥- | CN¥1.13 Billion | ▲ +5.1 pp |
| 2012 | 79.3% | CN¥563.64 Million | CN¥563.64 Million | CN¥- | CN¥710.51 Million | ▲ +17.2 pp |
| 2011 | 62.1% | CN¥410.17 Million | CN¥410.17 Million | CN¥- | CN¥660.17 Million | ▲ +19.6 pp |
| 2010 | 42.5% | CN¥238.88 Million | CN¥238.88 Million | CN¥- | CN¥561.59 Million | ▲ +28.8 pp |
| 2009 | 13.7% | CN¥72.03 Million | CN¥72.03 Million | CN¥- | CN¥525.08 Million | ▼ -29.7 pp |
| 2008 | 43.4% | CN¥59.76 Million | CN¥59.76 Million | CN¥- | CN¥137.79 Million | ▼ -7.7 pp |
| 2007 | 51.1% | CN¥55.14 Million | CN¥55.14 Million | CN¥- | CN¥107.91 Million | ▲ +3.6 pp |
| 2006 | 47.5% | CN¥30.56 Million | CN¥30.56 Million | CN¥- | CN¥64.39 Million | — |